.png)
Quick answer: Most health and wellness products (across pharmaceuticals, biotech, medtech, and personal care) fail not because the science is wrong but because commercial and R&D strategy are treated as sequential rather than parallel activities. Study design decisions made early in development lock in the addressable market, the defensible claim set, and ultimately the value of the asset. By the time commercial teams engage, those decisions are irreversible. The blueprint problem is that the commercial architect is rarely in the room when the foundations are being poured.
Early in my career in pharmaceuticals, I worked in an industry that had, by any measure, mastered the science of drug development. Extraordinary researchers. Rigorous stage gate processes. Billions invested in understanding molecular targets and clinical endpoints. And yet, drug after drug arrived at market having cleared every scientific hurdle, only to face a commercial landscape that nobody had properly prepared for. Narrow indications. Study designs that demonstrated statistical significance without generating the evidence payers actually needed. Products that were therapeutically real but commercially marginal because the decisions that determined their market position had been made years earlier, by people whose incentives had nothing to do with what happened after approval.
I left large pharma with a view that this was a large pharma problem. The bigger the organisation, the more siloed the functions, the greater the misalignment. What I have found since, working across biotech, medtech, cosmetic ingredients, and personal care, is that the problem is not a pharma problem at all. It is a science-led innovation problem. And it is getting worse, not better, as the industries adjacent to pharma move faster and with even less structural discipline.
The Structural Problem That Pharma Never Solved
In large pharmaceutical companies, R&D and commercial functions are typically separate organisations with separate leadership, separate incentive structures, and separate definitions of success. Most organisations separate R&D, regulatory, market access, manufacturing, and commercial into siloed functions with misaligned incentive structures. Clinical teams optimise for statistical significance at the primary endpoint. Commercial teams optimise for peak sales projections. No single function is accountable for the integrated outcome.
The consequences are predictable. Roughly two-thirds of new drug launches miss their first-year sales forecasts, and a meaningful share of those products never recover commercial momentum. The overall clinical drug development failure rate sits at approximately 90%, and while much of that is attributable to science (efficacy failures, safety signals, target validation) a significant proportion reflects something more tractable: programmes that were scientifically coherent but commercially misconfigured from the beginning.
The study design is where it happens. The choice of primary, secondary, and exploratory endpoints, comparator, patient population, and study duration in a Phase II trial are not just scientific decisions. They are commercial decisions. They determine which payer evidence standards the product will satisfy. They determine whether the label will support the indication the commercial team is planning to sell into. They determine whether a health technology assessment body will find the evidence compelling enough to recommend reimbursement at a price that makes the asset viable.
When R&D makes those decisions in a room without commercial representation - which, in my experience, was more often the rule than the exception - they make them on the basis of scientific merit, regulatory precedent, and the stage gate criteria in front of them. Those are legitimate inputs. They are not sufficient inputs. And by the time the commercial team sees the data package, it is too late to change anything.
What Happens When Smaller Organisations Replicate the Same Structure
The reasonable assumption is that smaller organisations such as early-stage biotechs, medtech startups, ingredient development companies, would be nimbler. Fewer people, less bureaucracy, faster iteration. The alignment problem should be easier to solve.
In practice, the opposite is often true. Approximately 75% of medtech ventures fail to generate a return for investors. Too often, startups fall into the trap of overengineering, prioritising technical advancements above clinical relevance or real-world adoption. The reason is not down to complexity, it has to do with composition. Early-stage health and wellness companies are typically founded by scientists. Exceptional ones, in many cases. People with deep expertise in a target, a mechanism, a molecule, or a material. What they often lack is not intelligence or commitment, it is the specific experience of having navigated the commercial decisions that determine whether a scientifically valid product becomes a commercially viable one.
In biotech specifically, the founding team's scientific conviction can actually work against commercial rigour. When you have spent years establishing that a target is real, that the mechanism is credible, that the preclinical data holds, the commercial questions can feel like a distraction rather than a foundational input. They should not be seen as a distraction, because the design decisions a product makes as it enters clinical research determines the addressable market. They determine the value of the asset, and they are extraordinarily difficult to reverse.
I have seen this pattern in novel cosmetic and personal care ingredient development as well, where the discipline is often even thinner. An ingredient concept emerges from a research lab or anecdotal customer feedback. A study is commissioned , often without a clear brief for what the study needs to demonstrate to make the ingredient commercially useful. The data comes back, and it is interesting, but it does not answer the questions that an NPD formulator, a retailer, or a regulatory body would actually need answered. The ingredient goes to market with a data package that was designed by scientists for scientists, and sits on the shelf of every distributor while the brand team tries to work out what claim it actually supports.
The Blueprint Problem, Stated Plainly
In construction, no builder breaks ground without an architect's blueprint. The blueprint does not constrain the engineer, it gives the engineer a clear brief. It tells them what the building needs to do, who will occupy it, what the structural requirements are, and what the finished product has to look like when the scaffolding comes down. Without the blueprint, a skilled construction team can produce an extraordinary piece of engineering that nobody wants to live in.
The commercial blueprint in health and wellness product development serves the same function. It is not a constraint on scientific ambition. It is a brief. It tells the R&D team what the product needs to demonstrate (to which population, against which comparator, measured by which primary, secondary, and exploratory endpoints) in order to be positioned defensibly in the market it is being developed for. It specifies which payer bodies need to be satisfied and what those bodies consider compelling evidence. It identifies the claim architecture the product needs to support and works backwards to the study design decisions that will make those claims defensible.
Most health and wellness organisations do not produce this blueprint before clinical development begins. Some produce a version of it during development, when it is already constraining rather than guiding the decisions being made. A significant proportion produce it after the data is in, which is not a blueprint at all, it is retrospective rationalisation.
The result, across pharma, biotech, medtech, and personal care ingredients, is the same. Products that are scientifically real, clinically valid, and commercially marginal, all because the decisions that determined their commercial position were made without a commercial NPD architect in the room.
Why This Is Getting Harder, Not Easier
The commercial environment that health and wellness products are entering is more demanding than it was a decade ago, across every category. Payers are more rigorous. Retailers are more scrutinising. Regulators are requiring more specific evidence. Consumers are more sceptical of unsubstantiated claims. Class action plaintiff attorneys are more active in the personal care and supplement space than they have ever been.
Each of these trends raises the bar for what a product needs to demonstrate to achieve market access at a price that justifies the investment in developing it. And each of them makes the cost of a poorly specified blueprint higher. A study designed without payer evidence standards in mind is not just a "missed opportunity", it is a product that may not be reimbursable at any price. A cosmetic ingredient developed without a clear claim architecture is not just hard to market, it may not be able to make any claim that regulator or formulators will accept.
Large Pharma has tolerated a degree of this misalignment for decades because the commercial scale of successful drugs could absorb the cost of failed ones. This margin of error is not acceptable to the organisations that represent the majority of health and wellness innovation now. Early-stage biotechs, ingredient developers, and medtech startups do not have that buffer. Every programme needs to have a credible commercial case from the beginning, not as a constraint on the science, but as the brief that makes the science commercially purposeful.
Further reading
This post connects to several pieces in the Parallaxis Insights series that cover the specific decisions the commercial blueprint needs to address. For the evidence requirements that determine claim defensibility across TGA, FTC, and ACCC frameworks, see our guide to how much evidence is enough and how the substantiation threshold moves by claim type. For the specific commercial and regulatory considerations for biotech companies considering Australia as a clinical development jurisdiction, our piece on Australia's R&D Tax Incentive and what biotech founders need to know covers the intersection of development economics and commercial strategy in detail.
Frequently asked questions
Why do so many health and wellness products fail commercially despite strong science?
The most common cause of commercial failure in health and wellness products is not scientific inadequacy but structural misalignment between R&D and commercial functions. Study design decisions made early in development (choice of primary, secondary, and exploratory endpoints, comparator, patient population, and study duration) determine what claims the product can make, which payer evidence standards it satisfies, and ultimately its addressable market. When those decisions are made without commercial input, they often produce data packages that are scientifically valid but commercially insufficient.
What is the pharmaceutical R&D and commercial misalignment problem?
In large pharmaceutical organisations, R&D and commercial teams typically operate as separate functions with separate incentive structures. R&D teams are incentivised to advance programmes through stage gates and reach approval. Commercial teams are incentivised to achieve sales. Neither function is structurally accountable for the integrated outcome - a product that achieves approval and achieves viable commercial access at a sustainable price. This misalignment is well-documented: roughly two-thirds of new drug launches miss their first-year sales forecasts.
Does the same NPD misalignment problem affect biotech startups?
Yes, and often more acutely than in large pharma. Biotech startups are typically founded by scientists whose expertise is in the target or mechanism rather than in commercial strategy. The scientific conviction that drives early-stage development can work against commercial rigour, the commercial questions feel like a distraction from the science rather than foundational inputs to it. The design decisions made as a product enters clinical research determine the addressable market and the value of the asset, and they are very difficult to reverse once locked in.
How does poor NPD planning affect personal care and cosmetic ingredient companies?
In personal care and cosmetic ingredient development, study designs are often commissioned without a clear brief for what the study needs to demonstrate to make the ingredient commercially useful. The result is data packages designed by scientists for scientists. They are interesting mechanistically but unable to support the specific claims that finished product brands, retailers, or regulators need. The ingredient reaches market without defensible claim architecture, and the commercial value of the development investment is substantially unrealised.
What does "commercial blueprint" mean in health and wellness product development?
A commercial blueprint is the strategic brief that specifies what a product needs to demonstrate (to which population, against which comparator, measured by which primary, secondary, and exploratory endpoints) n order to be positioned defensibly in its target market. It identifies the payer evidence standards the product needs to satisfy, the claim architecture it needs to support, and the regulatory pathway it needs to navigate. It is the commercial equivalent of an architect's blueprint: not a constraint on the science, but a brief that makes the science commercially purposeful.
When should commercial strategy be introduced into health and wellness NPD?
Before clinical development begins, not after the data is in. The study design decisions that are made as a product enters Phase I and Phase II clinical research determine the claim set, the addressable market, and the asset value. Introducing commercial strategy after those decisions are locked in is not strategic input — it is retrospective rationalisation. Organisations that integrate commercial and evidence strategy from the earliest stages of development consistently produce products that are better positioned for market access and more defensible under regulatory scrutiny.
How Parallaxis helps
Working across pharmaceutical development and now across health and wellness industries, we built Parallaxis specifically to address the blueprint problem. We bring commercial and evidence strategy into the room before the study design decisions are made; helping biotech founders, ingredient developers, medtech teams, and personal care brands build the brief that makes their science commercially purposeful. That means specifying the claim architecture before the protocol is locked in, mapping the evidence requirements to the market access standards that actually matter, and building NPD processes that are rigorous without being slow. If you are developing a product and want commercial strategy in the room before the foundations are poured, get in touch.